BioVaxys Technology (BioVaxys Technology) Accounts Payable & Accrued Expense : $1.54 Mil (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Accounts Payable & Accrued Expense?

BioVaxys Technology's quarterly accounts payable & accrued expense declined from Jan. 2023 ($1.40 Mil) to Apr. 2023 ($1.30 Mil) but then increased from Apr. 2023 ($1.30 Mil) to Jul. 2023 ($1.54 Mil).

BioVaxys Technology's annual accounts payable & accrued expense declined from Oct. 2020 ($0.68 Mil) to Oct. 2021 ($0.26 Mil) but then increased from Oct. 2021 ($0.26 Mil) to Oct. 2022 ($1.20 Mil).

BioVaxys Technology Accounts Payable & Accrued Expense Historical Data

The historical data trend for BioVaxys Technology's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Accounts Payable & Accrued Expense Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Accounts Payable & Accrued Expense

0.14

0.09

0.68

0.26

1.20

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1.31	1.20	1.40	1.30	1.54

BioVaxys Technology Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.